Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Novo Nordisk today announced data demonstrating that Wegovy® delivers substantial and consistent weight-loss results for women.
-
Novel alternative to GLP-1 drugs: Phase I data demonstrate fat mass reduction, preservation of lean mass, 80% responder rate, and no serious adverse events
-
Higher-dose Wegovy led to up to 28% weight loss, mainly from fat, with muscle preserved, new trial data show.
-
Serotonin Centers highlights its 5-Day Live Training Program as a cornerstone of franchise support, team performance and operational consistency.
-
Gala Health under investigation? Compounded tirzepatide & HRT telehealth: $149/mo, all 50 states, no insurance, licensed providers.
-
JellyFit scam or legit? The 8-ingredient gelatin trick drops — ACV, pectin, beet root — evaluated. 60-day guarantee.
-
High Point, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Bethany Medical has expanded its Pain Management & Weight Loss practice specialties with the addition of 3 new physicians and 2 Nurse...
-
Serotonin Centers opens in Fort Worth, bringing physician-led longevity care, hormone optimization and medical weight loss to North Texas.
-
NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting
-
Wegovy® injection is the first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU